RxDoctor Payments Data

Samantha Frazier, PA

Medical · Laurel, MDNPI 1427487784

Payments from drug & device makers

$133in general payments, 2019–2025

Across 7 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$23
  • E.r. Squibb & Sons, L.L.C.$22
  • GSK$19
  • Astellas Pharma US Inc$18
  • Bayer$18
  • Otsuka America Pharmaceutical, Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$133 in reported general payments places this provider in the 30th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$100,220
Medicare patients
126
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$56,326
JardianceEmpagliflozin47$34,999
TrulicityDulaglutide20$29,092
RexultiBrexpiprazole18$25,377
OzempicSemaglutide23$24,087
JanuviaSitagliptin Phosphate41$22,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,111
FarxigaDapagliflozin Propanediol14$9,072
EntrestoSacubitril/Valsartan12$8,127
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$4,455
Incruse ElliptaUmeclidinium Bromide11$3,655
OxycontinOxycodone Hcl20$3,544
Sucralfate41$3,433
Memantine Hcl63$3,047
Buspirone Hcl120$2,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$17$25,37718 claims
Novo NordiskOzempic$23$24,08723 claims
GSKTrelegy Ellipta, Incruse Ellipta$19$21,76637 claims
NovartisEntresto$16$8,12712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 543 medical providers in Maryland.

Other medical in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →